Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761876 | 0.83 | KDM4E (0.53) | HIF1ANQO1KDM4EMAPTALDH1A1 | |
| SCHEMBL2761830 | 0.82 | NQO1 (0.54) | EGLN1NQO1KDM4EMAPTMEN1 | |
| SCHEMBL2231601 | 0.82 | MTNR1A (0.49) | HIF1AKDM4EALDH1A1HPGD | |
| SCHEMBL2761688 | 0.82 | L3MBTL1 (0.52) | HIF1ANQO1 | |
| SCHEMBL2761878 | 0.81 | NQO1 (0.49) | NQO1KDM4ENPC1MAPTRAB9A | |
| SCHEMBL2761959 | 0.80 | NQO1 (0.54) | HIF1AEGLN1NQO1CA12CA9 | |
| SCHEMBL2762160 | 0.80 | CA12 (0.62) | EGLN1CA12CA9 | |
| SCHEMBL2761574 | 0.80 | HIF1A (0.53) | HIF1A | |
| SCHEMBL2761739 | 0.79 | LMNA (0.44) | HIF1AEGLN1KDM4EALDH1A1HPGD | |
| SCHEMBL2761685 | 0.78 | HIF1A (0.47) | HIF1AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EGLN1 5/4885NQO1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.